Some six years after picking up Seattle’s Universal Cells for $102 million, Astellas Pharma is opening a second location for ...

The Japanese big pharma adds the new gene therapy candidate to its pipeline in a US$50 million deal in equity and upfront ...

Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity ...

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) ...

Astellas has added another gene therapy to its pipeline, taking an option on a clinical-stage candidate for a rare genetic ...

Biosciences, Inc., a wholly-owned subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has ...

Cambridge’s Camp4 Therapeutics Inc. and Waltham’s Upstream Bio Inc. will both make their debuts on the public markets Friday.

UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license ...

AviadoBio and Astellas Pharma announced an exclusive option and license agreement for AVB-101, an investigational, AAV-based gene ...

Sutro Biopharma (STRO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Reni ...